The two lines of prior-chemo group tended to have more advanced disease, indicated by a smaller proportion having PS 0 and WHO’s cancer pain ladder 0, and a higher median PSA value, even compared with the overall prior-chemo group. This evidence concerns the gene KLK3 and cancer.